Nodality lands $10M to treat malignancies and autoimmune disease
Nodality, developer of diagnostics used to identify bloodstream malignancies and autoimmune disorders, has brought in $10 million of a $13.5 million round of equity. Based in South San Francisco, the company is backed by Kleiner Perkins Caufield & Byers, Maverick Capital and TPG Biotechnology.
Next Story: VigLink grabs funds from Google for link monetization
Previous Story: Kapow punches through with $1.5M for real-time data delivery
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
